Go Deep
Jenburkt Pharmaceuticals Limited
Jenburkt Pharmaceuticals Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 23,925 | 12.2 | 2.04 | 0.01 | 910.00 |
| Oct 2026 | 23,772 | 12.2 | 2.04 | 0.01 | 910.00 |
| Oct 2026 | 23,772 | 12.2 | 2.04 | 0.01 | 910.00 |
| Oct 2026 | 23,828 | 12.1 | 2.02 | 0.01 | 900.40 |
| Oct 2026 | 23,911 | 12.1 | 2.02 | 0.01 | 900.40 |
| Oct 2026 | 23,881 | 12.2 | 2.03 | 0.01 | 905.55 |
| Oct 2026 | 23,235 | 12.0 | 2.00 | 0.01 | 891.40 |
| Oct 2026 | 22,788 | 12.8 | 2.14 | 0.01 | 954.20 |
| Oct 2026 | 22,829 | 12.7 | 2.12 | 0.01 | 947.10 |
| Oct 2026 | 22,829 | 12.7 | 2.12 | 0.01 | 947.10 |
| Oct 2026 | 22,363 | 12.7 | 2.12 | 0.01 | 947.10 |
| Oct 2026 | 22,363 | 12.7 | 2.12 | 0.01 | 947.10 |
| Oct 2026 | 22,500 | 12.4 | 2.07 | 0.01 | 924.45 |
| Oct 2026 | 22,531 | 12.4 | 2.06 | 0.01 | 919.15 |
Jenburkt Pharmaceuticals Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 355,120,000.0 | 446,323,000.0 | 430,239,000.0 | — |
| Net Profit | 58,856,000.0 | 108,495,000.0 | 59,314,000.0 | — |
| EPS | 13.3 | 24.6 | 13.4 | 23.0 |
Jenburkt Pharmaceuticals Limited Revenue & Profit: Last 4 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 1,683,136,000.0 | 1,513,652,000.0 | 1,416,334,000.0 | 1,361,405,000.0 |
| Net Profit | 347,360,000.0 | 320,606,000.0 | 259,773,000.0 | 246,070,000.0 |
| EPS | 78.7 | 72.7 | 58.9 | 53.9 |
Jenburkt Pharmaceuticals Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 2,260,126,000.0 | 1,961,860,000.0 | 1,650,994,000.0 | 1,418,121,000.0 | — |
| Total Liabilities | 289,724,000.0 | 244,090,000.0 | 201,591,000.0 | 194,224,000.0 | — |
| Total Equity | 1,970,402,000.0 | 1,717,770,000.0 | 1,449,403,000.0 | 1,223,897,000.0 | — |
Owes vs Owns
Jenburkt Pharmaceuticals Limited owed ₹0.13 for every ₹1 it owned in Mar 2026, down from ₹0.14 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.13× | 0.12× | 0.12× | 0.14× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Jenburkt Pharmaceuticals Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 20.9%Receivables 10.8%Inventory 6.0%Fixed assets (tangible) 28.9%Long-term investments 25.7%Other assets 7.6%
How it's funded — Mar 2026
Long-term debt 0.8%Payables 3.6%Other liabilities 8.4%Shareholders' equity 87.2%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 47.3 | 23.1 | 74.0 | 49.5 |
| Receivables | 24.4 | 20.7 | 19.5 | 17.0 |
| Inventory | 13.6 | 8.9 | 8.6 | 8.3 |
| Fixed assets (tangible) | 65.3 | 56.6 | 36.5 | 22.7 |
| Intangible assets | 0.2 | 0.2 | 0.4 | 0.2 |
| Long-term investments | 58.1 | 76.5 | 17.4 | 34.4 |
| Other assets | 17.1 | 10.1 | 8.8 | 9.7 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 2.0 | 0.0 | 2.4 |
| Long-term debt | 1.8 | 1.5 | 0.0 | 0.0 |
| Payables | 8.1 | 8.2 | 6.3 | 6.1 |
| Other liabilities | 19.0 | 12.8 | 13.9 | 10.9 |
| Shareholders' equity | 197.0 | 171.8 | 144.9 | 122.4 |
| Net tangible assets | 196.8 | 171.5 | 144.6 | 122.2 |
Jenburkt Pharmaceuticals Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 265,218,000.0 | 279,060,000.0 | 81,238,000.0 | 170,520,000.0 | — |
| Investing Activities | -194,503,000.0 | -170,447,000.0 | -5,804,000.0 | 26,179,000.0 | — |
| Financing Activities | -88,592,000.0 | -76,219,000.0 | -70,779,000.0 | -210,413,000.0 | — |